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ABSTRACT
A general practitioner decided that a first-time Scandinavian seafarer with hyperactivity disorder, reason-
ably well-regulated on dextroamphetamine, was fit for unrestricted work at sea. Carrying amphetamine
across US borders is drug smuggling, and when the cruise ship could not supply his medication from local
ports, his behaviour became so erratic that he had to be signed off. Doctors providing medical fitness certi-
ficates for work at sea must understand the special requirements of seafaring life, know details about medi-
cine use restrictions aboard, and be familiar with international import bans and national prescription regula-
tions for controlled substances.
(Int Marit Health 2012; 63, 4: 204–206)
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CASE REPORT
A young man from Scandinavia was hired as a maritime
officer on a ship carrying a flag of convenience and doing
one-week-cruises from a US port. This was his first time at
sea and he saw a general practitioner in his home country
for his pre-employment medical examination (PEME). Not
authorised by the country’s maritime authorities to perform
national PEMEs, the physician had the seafarer fill out a ‘per-
sonal declaration’ in which he acknowledged that he had
a ‘psychiatric condition’ and took medication. Under ‘Com-
ments’ the examining physician referred to an enclosed doc-
ument from the seafarer’s psychiatrist stating the following:
‘ICD-10 Hyperkinetic Disorder – F90.1. Mr. NN has had
his condition since childhood, but he wasn’t diagnosed until
2005 at a university hospital. He began treatment with
a central stimulant. When he moved back to his home town,
further prescription of these drugs has been made by me.
His actual medication is dextroamphetamine 60–75 mg
a day. If he starts working in the USA, he will be in need of
a local US doctor to prescribe this medication, alternatively
that he is allowed importing his medication from his home
country. The first solution is the safest in most ways’.
All physical findings were normal, and the examining
doctor’s decision was: ‘Fit for work’.
The seafarer only brought a small supply of his medica-
tion at sign-on, and when the ship could not supply him
with dextroamphetamine, his behaviour soon became er-
ratic to the extent that the ship’s physician concluded that
it was unsafe to keep him aboard. The seafarer was then
sent ashore for a local psychiatric evaluation prior to medi-
cal sign-off and repatriation.
DISCUSSION
During the consultation the examining physician found
the seafarer somewhat hyperactive but highly motivated to
try to work at sea. Being stable on medication and thus fit
for work ashore, the physician thought that he should also
be able to work on a cruise ship, not being aware of any
particular restrictions for seafaring.
The laws of most maritime countries require that all
seafarers carry a valid medical certificate [1]. It shall en-
sure that the seafarer being examined is medically fit to
perform his or her routine and emergency duties at sea
safely and effectively and is not suffering from any medical

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conditions likely to be aggravated by service at sea, to ren-
der him or her unfit for service or to endanger the health of
other persons on board or the safety of the ship [1].
Major shipping nations have detailed requirements for
approving doctors for conducting PEMEs for seafarers on
their registered ships. The approved doctors act as agents
of the national maritime authorities, and when assessing
whether the published medical standards are met, they must
follow the procedures set out in detailed manuals [2, 3].
The UK Approved Doctor’s Manual [2] emphasizes that the
occupational circumstances that apply at sea should be fully
considered when a decision on a seafarer’s medical fitness
is taken. An unrestricted medical certificate will enable the
seafarer to work anywhere in the world. The examining doc-
tor should have knowledge of the living and working condi-
tions on board ships and an understanding of the demands
of the different types of work involved. Particular factors to
take into account are:
— the potentially hazardous nature of seafaring, which calls
for a high standard of health and continuing fitness;
— the restricted medical facilities likely to be available on
board ship (few ships carry doctors, and first aid train-
ing for crews is limited);
— the likelihood of limited medical supplies and delay be-
fore full medical treatment is available;
— the possible difficulty of providing/replacing required
medication; as a general rule a seafarer should not be
accepted if the loss of a necessary medicine could pre-
cipitate the rapid deterioration of a medical condition;
— the limited crew complements, which mean that illness
of one crew member may place a burden on others or
compromise the safe and efficient working of the ship;
— the potential need for crew members to play a role in an
emergency or emergency drill, which may involve strenu-
ous physical activity in adverse conditions;
— the confined nature of life on board ship and the need
to be able to live and work in a closed community;
— the likelihood that a seafarer will need to join and leave
ships by air, which means that they should be free from
any condition which precludes air travel or could be se-
riously affected by it;
— the especially high levels of physical fitness required for
work on some vessels;
— the area of operation of the vessel; this and the effects
of climate will affect the risk of diseases and the pat-
tern of work and rest;
— the demands that work at sea, especially the effects of
fatigue, poor management, or perceived injustice, which
can have an adverse effect on mood, provoke mental dis-
tress (stress), and exacerbate pre-existing conditions, and
the strain of emergencies at sea that can also lead to simi-
lar ill-effects [2].
While national fitness standards for seafarers vary wide-
ly, even flag of convenience registries demand PEME certi-
ficates in accordance with the International Convention on
Standards and Training, Certification and Watchkeeping for
Seafarers 1978, as amended (STCW), and the International
Labour Organisation (ILO) Maritime Labour Convention,
2006 (MLC 2006) requirements [4]. ILO ‘Guidelines on the
medical examinations of seafarers’ [1] provides practical
advice on how to comply with these globally ratified conven-
tions. On disorders of attention, e.g. attention-deficit/hyper-
activity disorder (ADHD), it says that a certificate should not
be issued if the condition is considered to have safety-criti-
cal consequences.
ADHD is a childhood onset psychiatric disorder that can
persist into adulthood in up to 50% of patients. It is charac-
terised by hyperactivity, mood instability, irritability, difficul-
ties in maintaining attention, lack of organisation, and im-
pulsive behaviour [5]. Untreated adults with ADHD often have
chaotic lifestyles, may appear to be disorganised, and may
rely on non-prescribed drugs and alcohol to get by [6]. The
Swedish Medical Products Agency recommends pharmaco-
logical treatment for ADHD only when other supportive in-
terventions have failed, indicating that pharmacologic ADHD
treatment most likely represents an indicator of the more
severe cases of ADHD [7]. Central stimulants, such as am-
phetamines, are highly efficacious in the treatment of ADHD
[8], and a Swedish study showed that rates of criminality
were lower during periods when ADHD patients were receiv-
ing central stimulants [7].
Cognitive, behavioural, and mental health conditions are
among the most difficult to assess during a clinical consul-
tation [2]. However, in our patient both his hyperactivity dia-
gnosis and his medication were known. He was deemed
reasonably stable ashore while on a daily dose of dextro-
amphetamine in a range that should be used only with cau-
tion, with frequent monitoring of side effects [8]. Proper psy-
chiatric monitoring is unrealistic even on cruise ships with
medical personnel aboard. Well-regulated ashore does not
mean that the person will remain stable on a busy ship where
numerous stress factors may adversely influence mental con-
ditions as well as medication compliance. Risk of recurrence
is likely to be increased at the time when any medication is
reduced or stopped [2], as demonstrated in our patient.
There are many reservations concerning use of medication
aboard [1–4]. The UK Approved Doctor’s Manual [2] state that
severe ADHD is unlikely to be compatible with work in any senior
jobs at sea where vigilance is needed, and as the commonly
used medication is also used as a drug of abuse, safe custody
on board may be a problem. Furthermore, on UK-registered ships
stimulants other than caffeine are not generally acceptable [2],
while the use of medication that can be addictive is not permit-
ted on Norwegian vessels [3].
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A particular problem in our case was that amphetamine
is a controlled substance all over the world and as such is
subject to severe legal restrictions. Carrying even small
amounts of amphetamine into the USA is a criminal act
and may have grave consequences. Import of small
amounts for personal medicinal use necessitates a spe-
cial license, and medication for long-term use must be
prescribed by a US physician with a special license [9]. It
should be noted that ship’s doctors are not authorised to
order controlled substances for their medical practice
aboard foreign ships from US drug stores in port. Also, the
supply of any type of medicine to cruise ships in an Amer-
ican port causes logistical problems, especially during busy
week-end turn-around.
Most shipping companies insist that all medicine use by crews
must be registered by the Master — or on cruise vessels by the
ship’s doctor. Crewmembers tend to bring remedies from home
for self-medication, but some of them contain substances that
will turn urine drug tests positive. As a consequence of interna-
tional ‘zero tolerance’ policies, crewmembers on most cruise ships
are routinely tested — randomly and for cause. Use of medica-
tion that has not been approved and documented on board pri-
or to a positive drug test is reason for summary disciplinary dis-
missal (breach of contract).
CONCLUSIONS
In conclusion, our case illustrates that declaring an ADHD
patient on dextroamphetamine fit for work at sea may have
serious consequences. Doctors performing PEMEs must
have a clear understanding of the special requirements of
seafaring life, know details about medicine use restrictions
aboard, and be familiar with international import bans and
national prescription regulations for controlled substances.
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